Concept Life Sciences appoints Philip Payne as Chief Commercial Officer
News Oct 24, 2017
Concept Life Sciences announced it has appointed Philip Payne as Chief Commercial Officer, to support the group’s continued growth. Philip completes Concept’s leadership team, following the appointment in August of John Handley as COO.
Philip will work with Concept’s executive team and board to drive the group’s commercial strategy, leading the business development function and helping to guide the next stage of the Company’s growth. He will be responsible for managing the sales team, including identification of new service areas, geographies and markets, supporting the broadening of Concept’s reach into Europe and the US.
Philip has 27 years’ experience in managing the integration of business development in an international environment, and has gained cross-sector expertise through roles in pharma and biotech discovery as well as analytical and development services. He joins Concept from Aptuit, where he held various roles, including Vice President of Sales, and was responsible for the global business development team and strategic accounts. Prior to joining Aptuit he was Business Development Director Europe and Asia for Sterile Technologies at Catalent Pharma Solutions, and Pharmaceutical Business Development Director with Reading Scientific Services Ltd.
Michael Fort, Executive Chairman, Concept Life Sciences, said: “Philip’s experience in managing multidisciplinary, international teams across a range of industries will be a great asset as Concept’s rapid rate of expansion continues. Following on from John’s appointment as COO, Concept now has an extremely strong leadership team. We are delighted to welcome Philip to the group.”
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “I am excited to join Concept at this pivotal stage in the growth of the Company, and look forward to working with the team to meet the group’s commercial and strategic objectives.”
A team of researchers has now created 3D maps of MT1 and MT2 melatonin receptors revealing the structural basis of the selectivity of each receptor subtype. They intend to use this structural information to design drug molecules that better target and bind to each of the two receptors.READ MORE
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE